Literature DB >> 8390846

Assessment of tumour vascularity as a prognostic factor in lymph node negative invasive breast cancer.

M E Van Hoef1, W F Knox, S S Dhesi, A Howell, A M Schor.   

Abstract

The association between tumour vascularity and relapse was examined in 93 patients with lymph node negative (LNN) invasive breast cancer. Factor VIII-related antibody was used to stain the microvessels. Vascularity was defined by the number of vessels per field counted in the area of highest vascular density at 100 x magnification. These vascular counts were divided into three groups of vascular density (group I: < 67, group 2: 68-100, group 3: > 101 vessels/field). Cross-tabulation analysis revealed a significant relationship between vascular density and tumour grade (P = 0.027). No association was found between vascularity and tumour size, tumour type, age or menopausal status. Survival analysis showed no association between vascularity and relapse-free (P = 0.92) or overall survival (P = 0.99). Significant associations between tumour grade and relapse-free (P = 0.0048) and overall survival (P = 0.0064) and between tumour size at the cut off of 15 mm diameter and relapse-free (P = 0.0097) and overall survival (P = 0.0271) were found. When grade was taken into account the effect of tumour size became non-significant (P = 0.059). Our results suggest that assessment of vascularity is not an independent prognostic factor in LNN invasive breast cancer.

Entities:  

Mesh:

Year:  1993        PMID: 8390846     DOI: 10.1016/s0959-8049(05)80304-1

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  35 in total

Review 1.  Intratumor microvessel density as a prognostic factor in cancer.

Authors:  N Weidner
Journal:  Am J Pathol       Date:  1995-07       Impact factor: 4.307

2.  Angiogenesis in oral squamous cell carcinoma.

Authors:  G Ascani; P Balercia; M Messi; L Lupi; G Goteri; A Filosa; D Stramazzotti; T Pieramici; C Rubini
Journal:  Acta Otorhinolaryngol Ital       Date:  2005-02       Impact factor: 2.124

3.  Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents.

Authors:  Y Kakeji; B A Teicher
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

Review 4.  Markers of tumor angiogenesis: clinical applications in prognosis and anti-angiogenic therapy.

Authors:  S B Fox; A L Harris
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

5.  Predictive value of the time-intensity curves on dynamic contrast-enhanced magnetic resonance imaging for lymphatic spreading in breast cancer.

Authors:  Shuhei Komatsu; Chol Joo Lee; Daisuke Ichikawa; Takashi Hamashima; Noriaki Morofuji; Koichi Shirono; Yohei Hosokawa; Harumi Okabe; Hideaki Kurioka; Hisakazu Yamagishi; Takahiro Oka
Journal:  Surg Today       Date:  2005       Impact factor: 2.549

Review 6.  Vasculogenic mimicry and tumor angiogenesis.

Authors:  R Folberg; M J Hendrix; A J Maniotis
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

7.  Diversity of the angiogenic phenotype in non-small cell lung cancer.

Authors:  Marc R McClelland; Shannon L Carskadon; Liujian Zhao; Eric S White; David G Beer; Mark B Orringer; Allan Pickens; Andrew C Chang; Douglas A Arenberg
Journal:  Am J Respir Cell Mol Biol       Date:  2006-11-01       Impact factor: 6.914

Review 8.  Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors.

Authors:  N Weidner
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

9.  The combination of angiogenesis and blood vessel invasion as a prognostic indicator in primary breast cancer.

Authors:  T Kato; S Kameoka; T Kimura; T Nishikawa; M Kobayashi
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

Review 10.  Intra-tumoural microvessel density in human solid tumours.

Authors:  J Hasan; R Byers; G C Jayson
Journal:  Br J Cancer       Date:  2002-05-20       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.